BACKGROUND: Inorganic polyphosphates (polyP), which are secreted by activated platelets (short-chain polyP) and accumulate in some bacteria (long-chain polyP), support the contact activation of factor XII (FXII) and accelerate the activation of FXI. OBJECTIVES: The aim of the present study was to evaluate the role of FXI in polyP-mediated coagulation activation and experimental thrombus formation. METHODS AND RESULTS: Pretreatment of plasma with antibodies that selectively inhibit FXI activation by activated FXII (FXIIa) or FIX) activation by activated FXI (FXIa) were not able to inhibit the procoagulant effect of long or short-chain polyP in plasma. In contrast, the FXIIa inhibitor, corn trypsin inhibitor, blocked the procoagulant effect of long and short polyP in plasma. In a purified system, long polyP significantly enhanced the rate of FXII and prekallikrein activation and the activation of FXI by thrombin but not by FXIIa. In FXI-deficient plasma, long polyP promoted clotting of plasma in an FIX-dependent manner. In a purified system, the activation of FXII and prekallikrein by long polyP promoted FIX activation and prothombin activation. In an ex vivo model of occlusive thrombus formation, inhibition of FXIIa with corn trypsin inhibitor but not of FXI with a neutralizing antibodies abolished the prothrombotic effect of long polyP. CONCLUSIONS: We propose that long polyP promotes FXII-mediated blood coagulation bypassing FXI. Accordingly, some polyp-containing pathogens may have evolved strategies to exploit polyP-initiated FXII activation for virulence, and selective inhibition of FXII may improve the host response to pathogens.
BACKGROUND:Inorganic polyphosphates (polyP), which are secreted by activated platelets (short-chain polyP) and accumulate in some bacteria (long-chain polyP), support the contact activation of factor XII (FXII) and accelerate the activation of FXI. OBJECTIVES: The aim of the present study was to evaluate the role of FXI in polyP-mediated coagulation activation and experimental thrombus formation. METHODS AND RESULTS: Pretreatment of plasma with antibodies that selectively inhibit FXI activation by activated FXII (FXIIa) or FIX) activation by activated FXI (FXIa) were not able to inhibit the procoagulant effect of long or short-chain polyP in plasma. In contrast, the FXIIa inhibitor, corntrypsin inhibitor, blocked the procoagulant effect of long and short polyP in plasma. In a purified system, long polyP significantly enhanced the rate of FXII and prekallikrein activation and the activation of FXI by thrombin but not by FXIIa. In FXI-deficient plasma, long polyP promoted clotting of plasma in an FIX-dependent manner. In a purified system, the activation of FXII and prekallikrein by long polyP promoted FIX activation and prothombin activation. In an ex vivo model of occlusive thrombus formation, inhibition of FXIIa with corntrypsin inhibitor but not of FXI with a neutralizing antibodies abolished the prothrombotic effect of long polyP. CONCLUSIONS: We propose that long polyP promotes FXII-mediated blood coagulation bypassing FXI. Accordingly, some polyp-containing pathogens may have evolved strategies to exploit polyP-initiated FXII activation for virulence, and selective inhibition of FXII may improve the host response to pathogens.
Authors: Heidi Grundt; Dennis Winston T Nilsen; Øyvind Hetland; Edward Valente; Hans Eirik Fagertun Journal: Am Heart J Date: 2004-02 Impact factor: 4.749
Authors: Stephanie A Smith; Sharon H Choi; Rebecca Davis-Harrison; Jillian Huyck; John Boettcher; Chad M Rienstra; Chad M Reinstra; James H Morrissey Journal: Blood Date: 2010-08-13 Impact factor: 22.113
Authors: Paola E J van der Meijden; Imke C A Munnix; Jocelyn M Auger; José W P Govers-Riemslag; Judith M E M Cosemans; Marijke J E Kuijpers; Henri M Spronk; Steve P Watson; Thomas Renné; Johan W M Heemskerk Journal: Blood Date: 2009-04-16 Impact factor: 22.113
Authors: Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink Journal: J Clin Invest Date: 2008-09 Impact factor: 14.808
Authors: Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt Journal: J Exp Med Date: 2005-07-11 Impact factor: 14.307
Authors: Novella M Bates; Cristina Puy; Patrick L Jurney; Owen J T McCarty; Monica T Hinds Journal: Cardiovasc Eng Technol Date: 2020-06-30 Impact factor: 2.495
Authors: Johan J F Verhoef; Arjan D Barendrecht; Katrin F Nickel; Kim Dijkxhoorn; Ellinor Kenne; Linda Labberton; Owen J T McCarty; Raymond Schiffelers; Harry F Heijnen; Antoni P Hendrickx; Huub Schellekens; Marcel H Fens; Steven de Maat; Thomas Renné; Coen Maas Journal: Blood Date: 2017-01-03 Impact factor: 22.113
Authors: Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani Journal: Blood Date: 2014-01-09 Impact factor: 22.113
Authors: Cristina Puy; Erik I Tucker; Anton Matafonov; Qiufang Cheng; Keith D Zientek; Dave Gailani; András Gruber; Owen J T McCarty Journal: Blood Date: 2015-01-13 Impact factor: 22.113
Authors: Jevgenia Zilberman-Rudenko; Stéphanie E Reitsma; Cristina Puy; Rachel A Rigg; Stephanie A Smith; Erik I Tucker; Robert Silasi; Alona Merkulova; Keith R McCrae; Coen Maas; Rolf T Urbanus; David Gailani; James H Morrissey; András Gruber; Florea Lupu; Alvin H Schmaier; Owen J T McCarty Journal: Arterioscler Thromb Vasc Biol Date: 2018-08 Impact factor: 8.311